We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Immune
Response Corporation announced that its Registration Statement for the resale of common stock underlying the convertible notes and warrants issued in the Company's March 2006 private placement financing was declared effective today by the Securities and Exchange Commission.
The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and sigma-tau Industrie Farmaceutiche Riunite SpA (sigma-tau), a leading Italian pharmaceutical group, announced the signature of a research and development (R&D) and commercialisation license agreement for istaroxime, a first-in-class luso-inotropic agent in clinical phase II for the treatment of acute heart failure syndromes.
DrugMax, Inc. today reported that preliminary April and May 2006 sales were $18.4 million and $19.0 million respectively, representing an 8.2% and 11.8% increase over April and May 2005 sales of $17.0 million and $17.0 million, respectively.
Wednesday, Panacos Pharmaceuticals, Inc., a biotechnology company, revealed data from studies on HIV Drug Resistance Program that indicated lack of rapid emergence of resistance to bevirimat in single multiple dose monotherapy studies in HIV infected patients.
KV Pharmaceutical Company, a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and generic/non-branded prescription pharmaceutical products, today reported results for the fourth quarter and fiscal year ended March 31, 2006, marking its 11th consecutive year of record revenues.
A new Rhode Island company called Analytical Edge has announced a partnership with Brown University to develop and market a statistical methodology designed to reduce the length and cost of clinical trials by cutting the average number of participants required and allowing more flexible data analysis.
The FDA's recent letter rejecting a citizen petition for OTC sale of the controversial contraceptive Plan B is meant to be a legal broadside, heading off Plan B lawsuits by making clear how solid the agency's legal footing is, a legal expert said.